NYC realtor sidelined city contract competitor as ‘direct result' of ties to top Mayor Adams aides: suit
Diana Boutross, a New York real estate broker, was able to sideline a competitor from a lucrative city government contract and secure the deal for herself as a 'direct result' of her close relationship with Ingrid Lewis-Martin and Jesse Hamilton, two longtime aides to Mayor Adams, according to an updated lawsuit.
The revised lawsuit comes as Boutross, Hamilton and Lewis-Martin, who resigned as the mayor's chief adviser in December, all remain under scrutiny from the Manhattan district attorney's office.
All three got their phones seized by DA investigators in September after returning from a trip to Japan, and Lewis-Martin was days after her resignation indicted on bribery and money laundering charges stemming from an alleged real estate scheme that appears unconnected to any dealings with Boutross and Hamilton.
DA prosecutors said in court last week they are pursuing other 'ongoing investigations' touching on Lewis-Martin, and that other 'targets' of those probes are connected to her.
The lawsuit in question was first filed last month by Boutross' competitor, JRT Realty, against her firm, Cushman & Wakefield.
The suit claimed Hamilton, a top official at the city Department of Citywide Administrative Services, pressured Cushman & Wakefield to install Boutross as its main executive on a contract with Adams' administration under which she'd broker commercial property deals between private landlords and city agencies in exchange for hefty commissions.
JRT, a subcontractor on the DCAS deal entitled to share in those commissions, charged in the original suit Cushman & Wakefield acquiesced to Hamilton's demand and put Boutross in the post in late 2023, at which point she took allegedly illicit steps to block JRT from deals.
But an amended complaint submitted in Manhattan Supreme Court late Wednesday alleges Boutross couldn't pull off those moves alone, but relied on her connections to Lewis-Martin and Hamilton to do so.
'[Boutross and her co-defendants] were able to do so only as a direct result of Boutross's personal relationships with Hamilton and Lewis-Martin,' JRT wrote in the updated complaint, which now names Boutross as well as two colleagues as defendants, in addition to Cushman & Wakefield itself, accusing them of defamation, contract breaches, tortious business intereference and other civil counts.
Specifically, JRT claims Boutross had help from Lewis-Martin and Hamilton in securing 'modifications' to the city's Minority and Women-Owned Business Enterprises rules that allowed Boutross to more easily block JRT from sharing in commissions. The firm, which is women-owned, alleges in the suit that city administrative and contract laws were violated in the process of those modifications being made.
Lewis-Martin, who has pleaded not guilty in her criminal case, isn't named as a defendant in JRT's suit, and neither is Hamilton.
Attorneys and reps for Lewis-Martin, Hamilton and Boutross didn't immediately return requests for comment Thursday. In response to JRT's original suit, attorneys for Cushman & Wakefield denied wrongdoing and filed a motion asking a judge to dismiss the accusations.
Also in the updated suit, JRT alleged Boutross hinted she had friends in high places when she spoke with JRT executives in mid-2023, before she was selected to take over the DCAS contract.
After the JRT executives explained to her the complexities of pulling off a DCAS brokering deal, Boutross, who allegedly had no prior government leasing experience, would respond, 'Don't worry. I have a rabbi,' according to the suit. The phrase is commonly used to denote a person with high-up connections that can make a difficult situation easy.
Around the same time of those talks, Hamilton had lunch with Boutross, her boss at Cushman & Wakefield and others, JRT alleges. In that lunch, Hamilton made clear to Boutross' boss that she should be tapped to oversee the contract with DCAS, according to court papers.
'She is my broker,' Hamilton said in the meeting, pointing at Boutross, JRT alleges.
A spokeswoman for DCAS didn't immediately return a request for comment on the amended JRT suit.
The lawsuit's playing out as Lewis-Martin's bribery case remains pending, with her lawyer and prosecutors meeting for a brief court hearing Thursday to discuss trial preparations. She has been indicted alongside her son, who allegedly received most of the bribes his mother accepted from two real estate developers in exchange for help with building permits.
Unlike Adams — whose federal corruption case is in the process of being at least temporarily dismissed by President Trump's administration — Lewis-Martin was indicted by local prosecutors who have shown no sign of wanting to drop her case.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
10 hours ago
- Miami Herald
Kayaker rescues 5-year-old ripped from tube, NY cops say. Two adults charged
A 5-year-old was pulled underwater after a current forced them off a tube, leaving them on a river island, New York troopers said. On June 7, troopers were sent after getting reports of a 5-year-old who was tubing with a group in a river in Canisteo, according to a news release by the New York State Police. The group included Tessa Hamilton, 32, and Matthew Martin, 35. When medical personnel arrived, they found the child with a group of adults in an area that wasn't accessible, troopers said. Police then used ropes to cross the river. Officers said they later learned Martin and Hamilton were tubing in the river with the child when a 'current pulled them into a partially submerged tree.' The child, who was not wearing a flotation device, fell into the water and was rescued by a kayaker, troopers said. The attempts to reach the group were not successful because of the hazardous conditions, so a boat was deployed to rescue the group, troopers said. The child was given medical attention and was sent to a hospital for further treatment before being released, troopers said. Investigators later learned Martin had an active 'stay-away Order of Protection' which didn't allow him to be in contact with Hamilton and the child, officers said. Hamilton was charged with reckless endangerment and endangering the welfare of a child, troopers said. Martin was charged with reckless endangerment, endangering the welfare of a child, and criminal contempt for violation of the active Order of Protection, troopers said. Canisteo is about a 300-mile drive northwest from New York City.
Yahoo
11 hours ago
- Yahoo
Green Cove Springs man arrested after SWAT callout
Bruce Allen Hamilton is under arrest in Clay County, following an armed standoff in Green Cove Springs Monday night. It happened on Cold Stream Lane. Deputies were called there to help a family who said Hamilton was drunk, armed and making threats toward family members. Advertisement >>> STREAM ACTION NEWS JAX LIVE <<< The Clay County Sheriff's Office sent its SWAT team. During the standoff, investigators said Hamilton fired shots toward deputies. After hours of negotiations, investigators said Hamilton surrendered peacefully. No one was hurt. Sheriff Michelle Cook issued this statement in a news release: 'Our deputies and specialized units demonstrated incredible restraint, discipline, and teamwork in resolving a volatile and dangerous situation. I'm grateful no one was injured and proud of the professionalism shown by everyone involved. This incident is a strong reminder of the risks our deputies face every day to protect this community.' Advertisement Hamilton is charged with two counts of aggravated assault and fifteen counts of aggravated assault on law enforcement officers. [DOWNLOAD: Free Action News Jax app for alerts as news breaks] [SIGN UP: Action News Jax Daily Headlines Newsletter] Click here to download the free Action News Jax news and weather apps, click here to download the Action News Jax Now app for your smart TV and click here to stream Action News Jax live.
Yahoo
20 hours ago
- Yahoo
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer will present a company overview live at the Life Sciences Virtual Investor Forum hosted by taking place June 11-12, 2025. DATE: Wednesday June 12, 2025 TIME: 1:00 – 1:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12, 13, and 16 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at To schedule a meeting with management outside of this event, investors can contact Michael Miller at mmiller@ Recent Company Highlights May 2025: Closed a private placement, which resulted in aggregate gross proceeds of $10 million priced at-the-market under Nasdaq rules. May 2025: Presented data from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed MASH in a late-breaking poster presentation at EASL Congress 2025. In this trial, DA-1241 significantly decreased plasma ALT levels, with a mean reduction of 22.8 U/L at 16 weeks, the Controlled Attenuation Parameter (CAP) Score improved by 23.0 dB/m, indicating reduced liver fat content, while an improvement in FibroScan-AST (FAST) score and NIS-4, supports beneficial effects on liver health. April 2025: Reported additional, positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity further demonstrating its best-in-class potential. DA-1726 demonstrated a clear dose-responsive trend in body weight reduction across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index, which shows body weight adjusted for height, showed a difference between the treatment group and the placebo group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. Of note, DA-1726 did not show any clinically significant increases in heart rate or QTcF changes up to 32 mg at 4 weeks of administration. April 2025: Announced positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity. DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity. The cohort receiving 32 mg of DA-1726 with no titration demonstrated a maximum reduction in body weight from baseline ranging up to -6.3%, and a mean body weight reduction of -4.3% at Day 26 (p=0.0005). Four out of six subjects on the 32 mg dose experienced mild gastrointestinal (GI) adverse events (AEs), most of which were resolved after 24 hours of occurrence. There were no treatment-related discontinuations or serious adverse events (SAEs). About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Contacts: MetaViaMarshall H. WoodworthChief Financial Officer+ Rx Communications GroupMichael Miller+1-917-633-6086mmiller@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data